Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

Published:2020-06 Issue:6 Volume:21 Page:843-850
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Sato Jun,Satouchi Miyako,Itoh Shoichi,Okuma Yusuke,Niho Seiji,Mizugaki Hidenori,Murakami Haruyasu,Fujisaka Yasuhito,Kozuki Toshiyuki,Nakamura Kenichi,Nagasaka Yukari,Kawasaki Mamiko,Yamada Tomoaki,Machida Ryunosuke,Kuchiba Aya,Ohe Yuichiro,Yamamoto Noboru

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Rare cancers are not so rare: the rare cancer burden in Europe;Gatta;Eur J Cancer,2011

2. Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese nationwide database study;Hishida;Eur J Cardio-thoracic Surg,2016

3. Chemotherapy definitions and policies for thymic malignancies;Girard;J Thorac Oncol,2011

4. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma;Lemma;J Clin Oncol,2011

5. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial;Thomas;Lancet Oncol,2015

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Bioequivalence Trial of Lenvatinib Mesylate Capsules in Healthy Subjects Under Fasting and Postprandial Conditions;Clinical Pharmacology in Drug Development;2024-09-10

2. Thymic epithelial tumor medical treatment: A narrative review;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. Lenvatinib in combination with pembrolizumab in heavily pretreated metastatic thymic carcinoma: A case report;Current Problems in Cancer: Case Reports;2024-09

4. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

5. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671);Annals of Oncology;2024-09